238 related articles for article (PubMed ID: 36244648)
1. HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.
Yuan J; Lv T; Yang J; Wu Z; Yan L; Yang J; Shi Y; Jiang L
Cell Mol Gastroenterol Hepatol; 2023; 15(2):307-325. PubMed ID: 36244648
[TBL] [Abstract][Full Text] [Related]
2. HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma.
Yuan J; Lv T; Yang J; Wu Z; Yan L; Yang J; Shi Y
Redox Biol; 2022 Dec; 58():102546. PubMed ID: 36423520
[TBL] [Abstract][Full Text] [Related]
3. The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition.
Yuan J; Lv T; Yang J; Wu Z; Yan L; Yang J; Shi Y; Jiang L
Cancer Lett; 2022 Nov; 549():215921. PubMed ID: 36122630
[TBL] [Abstract][Full Text] [Related]
4. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
5. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
[TBL] [Abstract][Full Text] [Related]
6. Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.
Dong Z; Huang K; Liao B; Cai H; Dong Y; Huang M; Zhou X; Jia Y; Xu L; Luo Y; Li ZP; Feng ST
Eur Radiol; 2019 May; 29(5):2272-2282. PubMed ID: 30547202
[TBL] [Abstract][Full Text] [Related]
7. Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction.
Wang TH; Hsueh C; Chen CC; Li WS; Yeh CT; Lian JH; Chang JL; Chen CY
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30201903
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
9. [The effects of microRNA-7 on proliferation and invasion of hepatocellular carcinoma HepG2 cells].
Qin AD; Liu XX; Li J; Liu J; Li YS
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):406-411. PubMed ID: 29936764
[No Abstract] [Full Text] [Related]
10. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway.
Tan G; Xie B; Yu N; Huang J; Zhang B; Lin F; Li H
Int J Clin Oncol; 2021 Mar; 26(3):532-542. PubMed ID: 33387087
[TBL] [Abstract][Full Text] [Related]
11. Y-box binding protein 1 augments sorafenib resistance
Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
[TBL] [Abstract][Full Text] [Related]
12. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
[TBL] [Abstract][Full Text] [Related]
13. The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
Zang HL; Ren SN; Cao H; Tian XF
IUBMB Life; 2017 Oct; 69(10):795-801. PubMed ID: 28861931
[TBL] [Abstract][Full Text] [Related]
14. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
15. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
16. A novel long non-coding RNA RP11-286H15.1 represses hepatocellular carcinoma progression by promoting ubiquitination of PABPC4.
Jiang X; Wang G; Liu Y; Mei C; Yao Y; Wu X; Chen X; Ma W; Li K; Zhang Z; Yuan Y
Cancer Lett; 2021 Feb; 499():109-121. PubMed ID: 33259899
[TBL] [Abstract][Full Text] [Related]
17. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
18. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
Liu J; Nie C
Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
20. Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma.
Li X; Yuan J; Song C; Lei Y; Xu J; Zhang G; Wang W; Song G
Cell Death Differ; 2021 Aug; 28(8):2315-2332. PubMed ID: 33649471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
